Addex Therapeutics (ADXN) Net Income towards Common Stockholders (2022 - 2025)
Historic Net Income towards Common Stockholders for Addex Therapeutics (ADXN) over the last 4 years, with Q2 2025 value amounting to $142225.5.
- Addex Therapeutics' Net Income towards Common Stockholders fell 9910.28% to $142225.5 in Q2 2025 from the same period last year, while for Sep 2025 it was -$12.6 million, marking a year-over-year decrease of 55152.47%. This contributed to the annual value of $8.0 million for FY2024, which is 16823.63% up from last year.
- According to the latest figures from Q2 2025, Addex Therapeutics' Net Income towards Common Stockholders is $142225.5, which was down 9910.28% from -$1.6 million recorded in Q1 2025.
- Addex Therapeutics' Net Income towards Common Stockholders' 5-year high stood at $15.9 million during Q2 2024, with a 5-year trough of -$11.1 million in Q4 2024.
- Its 4-year average for Net Income towards Common Stockholders is -$2.4 million, with a median of -$2.3 million in 2023.
- As far as peak fluctuations go, Addex Therapeutics' Net Income towards Common Stockholders tumbled by 79604.48% in 2023, and later skyrocketed by 76178.03% in 2024.
- Over the past 4 years, Addex Therapeutics' Net Income towards Common Stockholders (Quarter) stood at $1.5 million in 2022, then tumbled by 796.04% to -$10.4 million in 2023, then dropped by 6.67% to -$11.1 million in 2024, then skyrocketed by 101.29% to $142225.5 in 2025.
- Its Net Income towards Common Stockholders stands at $142225.5 for Q2 2025, versus -$1.6 million for Q1 2025 and -$11.1 million for Q4 2024.